Abstract
A major limitation in finding therapeutic solutions for Alzheimers disease (AD) has been the lack of a reliable method for early diagnosis of this devastating disease. Besides the development of biomarkers in biological fluids of patients, the search for a pathology-specific neuroimaging tools is critical at the present stage in which almost 30 million people suffer this disease worldwide. Several interesting approaches have been developed, however their clinical impact has been low. One of the difficulties has been to find the proper molecular tracers to specifically tag pathognomonic lesions in AD brain, including not only amyloid aggregates but also filaments of the modified microtubule-associated protein tau. In this review, we analyze the evidence towards developing pathology-specific diagnostic tools for AD. We analyze the current evidence and clinical implications of new imaging technologies for AD, and how tau hypothesis and the amyloid cascade hypothesis will impact on these scientific efforts in the near future.
Keywords: Alzheimer's disease, PET radiotracers, brain neuroimaging, benzimidazoles, tau protein, amyloid beta, AChEIs, NIH-ADAD, SPs, APP, Amyloid Cascade Hypothesis, FTDP17-T, PS-selective
Current Alzheimer Research
Title: Molecular Targets in the Rational Design of AD Specific PET Tracers: Tau or Amyloid Aggregates?
Volume: 8 Issue: 6
Author(s): L. E. Rojo, P. A. Gaspar and R. B. Maccioni
Affiliation:
Keywords: Alzheimer's disease, PET radiotracers, brain neuroimaging, benzimidazoles, tau protein, amyloid beta, AChEIs, NIH-ADAD, SPs, APP, Amyloid Cascade Hypothesis, FTDP17-T, PS-selective
Abstract: A major limitation in finding therapeutic solutions for Alzheimers disease (AD) has been the lack of a reliable method for early diagnosis of this devastating disease. Besides the development of biomarkers in biological fluids of patients, the search for a pathology-specific neuroimaging tools is critical at the present stage in which almost 30 million people suffer this disease worldwide. Several interesting approaches have been developed, however their clinical impact has been low. One of the difficulties has been to find the proper molecular tracers to specifically tag pathognomonic lesions in AD brain, including not only amyloid aggregates but also filaments of the modified microtubule-associated protein tau. In this review, we analyze the evidence towards developing pathology-specific diagnostic tools for AD. We analyze the current evidence and clinical implications of new imaging technologies for AD, and how tau hypothesis and the amyloid cascade hypothesis will impact on these scientific efforts in the near future.
Export Options
About this article
Cite this article as:
E. Rojo L., A. Gaspar P. and B. Maccioni R., Molecular Targets in the Rational Design of AD Specific PET Tracers: Tau or Amyloid Aggregates?, Current Alzheimer Research 2011; 8 (6) . https://dx.doi.org/10.2174/156720511796717203
DOI https://dx.doi.org/10.2174/156720511796717203 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
<i>Rhizoma Coptidis</i> for Alzheimer’s Disease and Vascular Dementia: A Literature Review
Current Vascular Pharmacology To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Is Educational Attainment Associated with Increased Risk of Mortality in People with Dementia? A Population-based Study
Current Alzheimer Research Perioperative Considerations in Diabetic Patients
Current Diabetes Reviews ABC Subfamily D Proteins and Very Long Chain Fatty Acid Metabolism as Novel Targets in Adrenoleukodystrophy
Current Drug Targets Combating Protein Misfolding and Aggregation by Intracellular Antibodies
Current Molecular Medicine DNA Methylation: An Epigenetic Insight into Type 2 Diabetes Mellitus
Current Pharmaceutical Design An Overview of Targeting Legumain for Inhibiting Cancers
Current Pharmaceutical Design The Histamine H3 Receptor as a Therapeutic Drug Target for Metabolic Disorders: Status, Challenges and Opportunities
Current Topics in Medicinal Chemistry Depression has a Strong Relationship to Alterations in the Immune, Endocrine and Neural System
Current Psychiatry Reviews Role of TREM2 in Alzheimer's Disease and its Consequences on β- Amyloid, Tau and Neurofibrillary Tangles
Current Alzheimer Research Biomarker Assessment in Nutritional Modulation of Oxidative Stress-Induced Cancer Development by Lipid-Related Bioactive Molecules
Recent Patents on Anti-Cancer Drug Discovery Identification and Detection of Transmissible Spongiform Encephalopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Commentary (Research Highlights: Targeted Inhibition of miR-155 Promotes Post-Stroke Neovascularization and Functional Recovery)
CNS & Neurological Disorders - Drug Targets An Overview of Phytochemical and Pharmacological Profile of <i>Morus alba</i> Linn
Current Bioactive Compounds A Brief Overview of Tyrosine Hydroxylase and α-Synuclein in the Parkinsonian Brain
CNS & Neurological Disorders - Drug Targets The Impact of Small Heat Shock Proteins (HspBs) in Alzheimer’s and Other Neurological Diseases
Current Pharmaceutical Design Vascular Contribution to Alzheimer Disease: Predictors of Rapid Progression
CNS & Neurological Disorders - Drug Targets Cystatin C: An Emerging Biomarker in Cardiovascular Disease
Current Topics in Medicinal Chemistry Effect of Simvastatin on Inflammatory Cytokines Balance in Air Pouch Granuloma Model
Inflammation & Allergy - Drug Targets (Discontinued)